Aditxt Inc(ADTX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1380.8 | Insider Own | 0.03% | Shs Outstand | 998.0M | Perf Week | - |
| Market Cap | 0.01B | Forward P/E | - | EPS next Y | - | Insider Trans | -84.45% | Shs Float | 0.4M | Perf Month | -80.96% |
| Enterprise Value | - | PEG | - | EPS next Q | - | Inst Own | - | Short Float | 69.72% | Perf Quarter | -99.93% |
| Income | - | P/S | 661.33 | EPS this Y | - | Inst Trans | - | Short Ratio | 0 | Perf Half Y | -100% |
| Sales | 0.00B | P/B | - | EPS next 5Y | - | ROA | - | Short Interest | 0.28M | Perf YTD | -99.99% |
| Book/sh | -861.43 | P/C | - | EPS past 3/5Y | 99.4% - | ROE | - | 52W High | -100% | Perf Year | -100% |
| Cash/sh | - | P/FCF | - | Sales past 3/5Y | -84.93% - | ROIC | - | 52W Low | - | Perf 3Y | -100% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 99.99% | Gross Margin | - | Volatility(W/M) | 219.76% 88.22% | Perf 5Y | -100% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | -74.09% | Oper. Margin | - | ATR (14) | 0.35 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | - | EPS Q/Q | - | Profit Margin | - | RSI (14) | 13.65 | Recom | - |
| Dividend Gr. 3/5Y | - | Current Ratio | - | Sales Q/Q | 1094.4% | SMA20 | -83.82% ($0.06) | Beta | 0.89 | Target Price | - |
| Payout | - | Debt/Eq | - | Earnings | - | SMA50 | -99.69% ($3.23) | Rel Volume | 0 | Prev Close | $0.01 |
| Employees | 26 | LT Debt/Eq | - | EPS/Sales Surpr. | - 120.59% | SMA200 | -100% | Avg Volume(3M) | 380.86M | Price | $0.01 |
| IPO | 2020/6/30 | Option/Short | No/Yes | Trades | 0 | Volume | - | Change | - |
Aditxt IncADTX | NASD | Biotechnology 🧬 A biotechnology company that develops and commercializes innovative biotechnology in the fields of immune health, precision medicine, and population health. Founded in 2017, Aditxt (ADTX) has a product portfolio leveraging immune profiling analysis, apoptosis-based immunotherapy, and diagnostic technology for mitochondrial genetic disorders.
Over the past 1 year, roughly in the middle
Traded less than usual. That is 0% of its average volume.
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $66,133. Peers typically go for $1,173.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -100.0%. The S&P 500 did +69% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Short interest is a burden
69.7% of the float is sold short.
Tap to view numbers
It ranks #507 of 595 in the industry
Based on market cap of $9M.
